ZhenGe Biotech

About ZhenGe Biotech

ZhenGe Biotech, established in 2017 by Chairman and CEO Jianxin Chen, operates as a contract development and manufacturing organization (CDMO) catering to the biopharmaceutical sector. The company was founded by a group of scientists returning from overseas and is strategically located in Shanghai's Pilot Free Trade Zone. Since its inception, ZhenGe Biotech has demonstrated a strong growth trajectory, marked by significant financing milestones, including a $51 million Series A in March 2020, a $70 million Series B in February 2021, and a substantial $100 million Series C round in January 2022, bringing its total funds raised to $225 million. This capital has been directed towards enhancing global research and development capabilities and expanding its GMP manufacturing capacity.

The company's business model is centered on providing comprehensive, end-to-end services that guide clients from the initial concept phase to commercialization. ZhenGe Biotech serves a clientele of over 100 biopharma and biotech companies, assisting them with the discovery, development, and manufacturing of biologics. Its revenue is generated by offering a suite of services that includes macromolecule developability analysis, cell line development, process development, and clinical sample production. The firm operates on an international scale, with facilities in Shanghai, China, and a wholly-owned subsidiary, Zencore Bio, in Maryland, USA, to support a global client base.

ZhenGe Biotech's service portfolio is designed to accelerate the R&D and commercialization of innovative biologics. The company possesses expertise in monoclonal and bispecific antibodies, antibody-drug conjugates (ADCs), fusion proteins, and vaccines. It provides integrated solutions that cover the entire drug development lifecycle, from preclinical research to commercial manufacturing. Key offerings include process characterization and validation, analytical services, and the development and production of mammalian cell culture media. The company has established a 10,000-square-meter GMP pilot production center and is constructing a commercial manufacturing base equipped with multiple bioreactors to meet growing demand.